long intergenic non-protein coding RNA 1090Genealiases: []
Q-omics provides the consensus-scored LINC01090 profile across patient tissues and cancer cell-line models. LINC01090 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LINC01090 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, LINC01090 RNA expression shows 9,475 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, THCA, and TGCT as cancer lineages where LINC01090 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01090 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01090 survival associations across molecular data types. LINC01090 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01090 RNA expression–survival associations across cancer types. High LINC01090 expression shows unfavorable associations in KIRC, COAD, LIHC, UVM and ESCA, but favorable associations in CHOL. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LINC01090 RNA expression.
This table summarizes LINC01090 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01090. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01090 shows lower tumor expression in THCA and BRCA and higher tumor expression in LIHC, KICH, KIRP and PAAD. The THCA box plot shows higher LINC01090 RNA expression in normal versus tumor tissue (log2 FC = −0.067, t-test p < 0.001).
This table shows molecular features associated with LINC01090 in patient tissues and cancer cell lines. In patient samples, LINC01090 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
